Asia Pacific Erythropoietin Drugs Market By Drug Class (Biologics and Biosimilars), By Product (Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and others), By Application (Renal Diseases, Cancer, Hematology and Neurology), By Country, Growth Potential, Industry Analysis Report and Forecast, 2021 - 2027
Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Get in-depth analysis of the COVID-19 impact on the Asia Pacific Erythropoietin Drugs Market
Market Report Description
The Asia Pacific Erythropoietin Drugs Market would witness market growth of 13.2% CAGR during the forecast period (2021-2027).
The increasing incidences of chronic diseases like cancer, end-stage renal diseases, and HIV are likely to boost the demand for EPO-stimulating agents. These diseases have the potential to cause anaemia. To control the increasing cases of anaemia, the demand for Erthropotin (EPO) drugs would witness a surge in the forthcoming years.
The molecular weight of erythropoietin is about 30,400 daltons. It is generated by mammalian cells in which the gene of the human erythropoietin gene is introduced. The product acts similar to natural erythropoietin and retains biological activity in the same manner as endogenous erythropoietin. Epoetin alfa biosimilar like Retacrit (epoetin alfa-epbx or epoetin zeta) has a formulation that allows more treatment options for patients suffering from anaemia.
In the Asia Pacific, EPO industry is flourishing due to a continuous increase in the incidence of chronic diseases. There is high demand for low-cost therapeutics in this region. Therefore, the Asia Pacific has attracted many companies for the development of biosimilars. They are focused on developing more biosimilars than any other place on the globe.
Moreover, supportive government initiatives will also provide better health amenities to the public in this region. It is expected to contribute to the EPO drug market growth. For example, the Japanese government’s regulation stated that on the price of biosimilars, a discount of 30% should be given and making it available at subsidized prices to people who belong to the lower economic class.
The China market dominated the Asia Pacific Hematology Market by Country in 2020, thereby, achieving a market value of $191 million by 2027. The Japan market is showcasing a CAGR of 15.5% during (2021 - 2027). Additionally, The India market is poised to grow at a CAGR of 15.5% during (2021 - 2027).
Based on Drug Class, the market is segmented into Biologics and Biosimilars. Based on Product, the market is segmented into Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and others. Based on Application, the market is segmented into Renal Diseases, Cancer, Hematology and Neurology. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Johnson and Johnson, Teva Pharmaceuticals Industries Ltd., Amgen, Inc., F. Hoffmann-La Roche Ltd., Biocon Limited, Intas Pharmaceutical Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., LG Corporation (LG Life Sciences Ltd.), and Celltrion, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Drug Class
- Renal Diseases
- South Korea
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Johnson and Johnson
- Teva Pharmaceuticals Industries Ltd.
- Amgen, Inc.
- F. Hoffmann-La Roche Ltd.
- Biocon Limited
- Intas Pharmaceutical Ltd.
- Sun Pharmaceutical Industries Ltd.
- Dr. Reddy’s Laboratories Ltd.
- LG Corporation (LG Life Sciences Ltd.)
- Celltrion, Inc.
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free